SARS-CoV-2 (COVID-19) Trimeric Spike (S) Recombinant Protein
| Code | Size | Price |
|---|
| PSI-10-075-0.1mg | 0.1mg | £1,028.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
blue ice or RT
Storage:
This recombinant protein may be stored as received at 2-8˚C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80˚C. Avoid Repeated Freeze Thaw Cycles.
Documents
Further Information
Application Note:
ELISA
Background:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The S protein is a transmembrane, homotrimeric, class I fusion glycoprotein that mediates viral attachment, fusion, and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits, S1 (~700 a.a) and S2 (~600 a.a), that mediate viral attachment and membrane fusion, respectively. S1 contains two major domains, the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD), which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor, the RBDs only share ~73% amino acid identity, and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3, 6. The RBD is dynamic and undergoes hinge-like conformational changes, referred to as the ?down? or ?up? conformations, which hide or expose the receptor-binding motifs, respectively 7. Following receptor binding, S1 destabilizes, and TMPRSS2 cleaves S2, which undergoes a pre- to post-fusion conformation transition, allowing for membrane fusion 8, 9. The S protein has been the main focus of therapeutic and vaccine design as it is highly immunogenic. Both neutralizing antibodies 10,11 and memory T cells 12,13 targeting the S protein are present in the sera of convalescent COVID-19 patients.
Background References:
- Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
- Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
- Wrapp D, Wang N, Corbett KS, et al. bioRxiv. 2020.02.11.944462. 2020.
- Walls AC, Park YJ, Tortorici MA, et al. Cell. 181(2):281-292.e6. 2020.
Buffer:
This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
NCBI Gene ID #:
1791269090
NCBI Official Name:
surface glycoprotein
NCBI Organism:
Severe acute respiratory syndrome coronavirus 2
Physical State:
Liquid
Predicted Molecular Weight:
The predicted molecular mass is ~132 kDa for monomer and ~396 kDa for trimer
Protein Accession #:
QHD43416.1
Purity:
>95% by SDS Page
Endotoxin level < 1.0 EU/mg as determined by the LAL method
Endotoxin level < 1.0 EU/mg as determined by the LAL method
Recombinant Protein Sequence:
#N/A
Source:
HEK293 cells